TD Asset Management Inc Has $412.13 Million Stock Holdings in Gilead Sciences, Inc. $GILD

TD Asset Management Inc cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the 4th quarter, Holdings Channel reports. The firm owned 3,357,740 shares of the biopharmaceutical company’s stock after selling 67,251 shares during the quarter. TD Asset Management Inc’s holdings in Gilead Sciences were worth $412,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of GILD. Brighton Jones LLC increased its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $215,000. Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the last quarter. Ieq Capital LLC increased its stake in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its stake in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 674 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive late-stage Livdelzi data in primary biliary cholangitis, reinforcing the drug’s commercial potential and supporting the company’s liver-disease growth story. Article Title
• Positive Sentiment: Additional coverage highlighted long-term efficacy and safety data for Livdelzi, which could help Gilead expand the drug’s reach in PBC. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, a sign that analyst confidence is improving.
• Positive Sentiment: Cencora said it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, helping Gilead’s cell-therapy business maintain access and commercialization momentum. Article Title
• Neutral Sentiment: Gilead remains in the spotlight because investors are closely watching the stock and the company’s broader pipeline, but that attention alone does not change fundamentals. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan, which can still create a modest headwind for sentiment despite being routine. Article Title

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $9,047,570 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on GILD shares. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target on the stock. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citigroup upped their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. Twenty-six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences Stock Up 1.1%

Shares of GILD opened at $128.99 on Thursday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The firm has a market cap of $160.15 billion, a P/E ratio of 17.57 and a beta of 0.31. The firm’s 50-day simple moving average is $134.74 and its 200 day simple moving average is $134.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.